Corcept Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Corcept Therapeutics's estimated annual revenue is currently $102.1M per year.
- Corcept Therapeutics received $493.9M in venture funding in July 2012.
- Corcept Therapeutics's estimated revenue per employee is $281,400
- Corcept Therapeutics's total funding is $80.1M.
Employee Data
- Corcept Therapeutics has 363 Employees.
- Corcept Therapeutics grew their employee count by 17% last year.
Corcept Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.4M | 2 | 0% | N/A | N/A |
#2 | $32M | 159 | 3% | N/A | N/A |
#3 | $35M | 121 | 3% | $62.5M | N/A |
#4 | $30.2M | 150 | 18% | N/A | N/A |
#5 | $135.3M | 673 | 0% | N/A | N/A |
#6 | $14.9M | 113 | 16% | $173M | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is Corcept Therapeutics?
Leading the field in the discovery of drugs that modulate the effects of cortisol. The adverse effects of excess cortisol have been Corcept's focus since the company's inception. Abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. In addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. All of these compounds competitively block the glucocorticoid receptor (GR), but not the progesterone receptor. Scientific literature suggests that competitive GR antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, Alzheimer's disease, alcoholism, prostate, breast and ovarian cancer, and weight gain caused by atypical anti-psychotic medications. We are investigating several of these indications in collaboration with researchers around the world.
keywords:N/A$80.1M
Total Funding
363
Number of Employees
$102.1M
Revenue (est)
17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Corcept Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO, President and Director | Reveal Email/Phone |
2 | Director Chemical Development | Reveal Email/Phone |
3 | VP, Marketing | Reveal Email/Phone |
4 | Chief Human Resources and Communications Officer | Reveal Email/Phone |
5 | Program Director, Development Team | Reveal Email/Phone |
6 | VP, Development Operations | Reveal Email/Phone |
7 | Director, Translational Science | Reveal Email/Phone |
8 | Senior Accounting Manager | Reveal Email/Phone |
9 | Director | Reveal Email/Phone |
10 | Regional Sales Manager - Florida | Reveal Email/Phone |
Corcept Therapeutics News
Insiders of Corcept Therapeutics Incorporated (NASDAQ:CORT) are probably glad they bought last year as their US$3.2m investment now stands at US...
MENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged...
MENLO PARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged...
Corcept Therapeutics Incorporated (NasdaqCM:CORT) announces a share repurchase program. Under the offer, the company will repurchase up to 10,000,000 shares. The shares will be repurchased at a price not greater than $23.75 nor less than $20.75 per share. The company intends to pay for the share ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $86M | 382 | N/A | N/A |
#2 | $63.2M | 383 | 67% | $106.3M |
#3 | $120.1M | 392 | 3% | N/A |
#4 | $106.9M | 401 | 16% | $178M |
#5 | $35M | 410 | 10% | N/A |
Corcept Therapeutics Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2006-11-16 | $3.0M | Undisclosed | Paperboy Ventures LLC | Article |
2007-08-21 | $10.1M | Undisclosed | Paperboy Ventures LLC | Article |
2008-03-28 | $25.0M | Undisclosed | Article | |
2011-01-24 | $Undisclosed | Undisclosed | Stifel Nicolaus Weisel and Lee | Article |
2012-07-03 | $493.9M | Undisclosed | Credit Suisse Securities (USA) | Article |
Corcept Therapeutics Executives
Name | Title |
---|---|
Joseph Belanoff | CEO, President and Director |
Sean Maduck | Chief Commercial Officer |
Charles Robb | Chief Financial Officer |
Amy Flood | Chief Human Resources and Communications Officer |
Andreas Grauer | Chief Medical Officer |
Charlie Robb | Chief Financial Officer |
Atabak Mokari | Chief Financial Officer |
Hazel Hunt | Chief Scientific Officer |
Joseph Belanoff | CEO, President and Director |
Amiel Balagtas | Vice President, Development Operations |
Susan Rinne | VP Regulatory Affairs |
Iulia Cristina Tudor | VP, Head of Biometrics |
Wei Dong | VP and Head of Safety |
Anne LeDoux | Vice President and Controller |
Bob Roe | President |
Gavin Williams | Vice President, Market Planning & Operations | General Manager |
Alan Arroyo | Vice President, Clinical Development Operations |
Vinita Kumar | Vice President and Head of the Department, Quality Assurance |
Tom Burke | Vice President, Sales and Marketing |
Gary Francesconi | Vice President, Legal & Compliance |
Behn Sarafpour | Vice President Medical Affairs |